Martin David Harp

Charles Wykoff, MD, PhD, spoke with the Ophthalmology Times team about the GALE study looking at pegcetacoplan for the management of geographic atrophy at this year's American Academy of Ophthalmology meeting.

Paul Runge, MD, FACS, spoke with Ophthalmology Times about his time in Ukraine treating retinopathy of prematurity (ROP) and implementing the Norlase Lion laser at this year's American Academy of Ophthalmology meeting.

XIPERE is the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis.

ABP 938 is an investigational biosimilar to EYLEA® (aflibercept).

Kodiak paused further development of tarcocimab last summer after its GLEAM and GLIMMER studies in diabetic macular edema did not meet their primary endpoint.

Launched in 2014, Intelligent Research in Sight is the nation's first and largest comprehensive eye disease registry.

The collaboration, fueled by a $5 million donation from Knights Templar Eye Foundation (KTEF), will introduce a free and open VR simulation program for ophthalmologists and trainees worldwide.

The Phase 3 DIAMOND trial of OCS-01 in Diabetic Macular Edema (DME) presents encouraging results, meeting primary and secondary endpoints.

A groundbreaking study conducted by the International Agency for the Prevention of Blindness (IAPB) and Kevin Frick, PhD, from Johns Hopkins University reveals that prioritizing better eye health could inject a staggering $50.4 billion annually into the US economy.

Academy’s 2023 program taking place in San Francisco.

This milestone was announced by Clearside Biomedical, Inc., Arctic Vision's partner. ARCATUS, also known as XIPERE®, utilizes a revolutionary suprachoroidal delivery platform, offering new hope to patients in China suffering from this vision-threatening condition.

The Person of Vision Award gala will be held on March 14, 2024.

The collaboration will drive an effort to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with serious eye diseases.

An increase in sexually transmitted infections may be causing an increase in number of eye infections.

The theme calls on employers, insurers, and policy makers to consider how they can contribute to improved access to vision and eye health care.

The week of September 18-24 will be dedicated to educating the public on IEDs such as uveitis, keratitis, conjunctivitis and more.

In this key role, Weil will lead the organization to commercial readiness from designing launch strategies for the US and globally.

Walgreens Boots Allianc Inc. and CVS Health are among the companies the FDA sent letters to for violating federal law.

The study from New Zealand was conducted on an otherwise healthy 28-year-old woman.

TRS01 demonstrates clear anti-inflammatory activity in noninfectious anterior uveitis with no evidence of significant adverse effects.

Priya Vakharia, MD, spoke with our team about her presentation at the Women in Ophthalmology Summer Symposium being held in Marco Island, Florida.

Maria H. Berrocal spoke with our team about her presentation at the Women in Ophthalmology Summer Symposium being held in Marco Island, Florida.

The company believes the 19-gauge filter needles may be the culprit in the SYFOVRE injections.

Eye symptoms such as dry, itchy, red, painful, watery, and gritty eyes can happen before the smoke is even noticeable.

Carl Regillo, MD, FACS, FASRS, spoke with our team following the annual ASRS meeting in Seattle, Washington to share insights from his presentation titled, "Modulation of Macrophages and Complement Dysfunction in Non-exudative AMD utilizing novel, sialic-acid coated nanoparticles." Aviceda Therapeutics is unlocking the proteogenomic code of AMD to target proteins and pathways linked to macular degeneration.

OSC-01 is a novel, high concentration preservative-free topical OPTIREACH formulation of dexamethasone.

Prevent Blindness has declared the month of August Children’s Eye Health and Safety Month. The goal of this initiative is to educate parents and caregivers on ways to keep children’s eyes healthy.

DAYLIGHT is the first of the company's 3 studies and was a randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of a high-intensity dosing regimen of tarcocimab tedromer.

Cognition Therapeutics has dosed the first participant in the phase 2 MAGNIFY study of CT1812. This oral therapy is being studied as a for geographic atrophy (GA) secondary to dry age-related macular edema (AMD).

Akari remains on track and plans to submit an IND application to the US FDA in the first half of 2024, and plans on starting clinical trials in the second half of 2024